Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iparomlimab and Tuvonralimab Injection”

32 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 32 results

Testing effectiveness (Phase 2)Looking for participantsNCT07290010
What this trial is testing

The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07493993
What this trial is testing

Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Who this might be right for
ESCC
Tianjin Medical University Cancer Institute and Hospital 26
Testing effectiveness (Phase 2)Looking for participantsNCT07232654
What this trial is testing

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

Who this might be right for
LOCALLY ADVANCED CERVICAL CANCERS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)Looking for participantsNCT07392346
What this trial is testing

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Who this might be right for
Gastric Cancer Adenocarcinoma Metastatic
Dai, Guanghai 68
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515469
What this trial is testing

A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Who this might be right for
HCC - Hepatocellular CarcinomaIparomlimab and Tuvonralimab InjectionNeoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT07099274
What this trial is testing

Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma

Who this might be right for
HCC
Tianjin Medical University Cancer Institute and Hospital 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07349225
What this trial is testing

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Who this might be right for
ES-SCLC
The Second Affiliated Hospital of Dalian Medical University 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07738159
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma

Who this might be right for
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)QL1706Lenvatinib+1 more
West China Hospital 92
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06958484
What this trial is testing

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

Who this might be right for
HCC - Hepatocellular CarcinomaAdjuvant Treatment
The Affiliated Hospital of Xuzhou Medical University 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07277972
What this trial is testing

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Who this might be right for
RCC, Renal Cell Cancer
Tianjin Medical University Cancer Institute and Hospital 36
Testing effectiveness (Phase 2)Looking for participantsNCT07289997
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

Who this might be right for
AFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4AFPGC+1 more
Hebei Medical University Fourth Hospital 39
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07372079
What this trial is testing

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

Who this might be right for
Breast CancerNeoadjuvant TherapyImmune Checkpoint Inhibitors+1 more
Tianjin Medical University Cancer Institute and Hospital 40
Not applicableNot Yet RecruitingNCT07046780
What this trial is testing

A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor CancerMetastatic Solid TumorsLocally Advanced
PENG YUAN 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07379398
What this trial is testing

Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
Tianjin Medical University Cancer Institute and Hospital 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07263360
What this trial is testing

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Who this might be right for
BTC
Tianjin Medical University Cancer Institute and Hospital 29
Very early researchLooking for participantsNCT07343791
What this trial is testing

Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.

Who this might be right for
DC-CIK TreatmentRegorafenibColorectal Cancer+2 more
JIANG LONGWEI 14
Testing effectiveness (Phase 2)Looking for participantsNCT06951997
What this trial is testing

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07833241
What this trial is testing

Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC

Who this might be right for
Borderline Resectable Pancreatic CancerHigh-Risk Resectable Pancreatic Cancer
Shanghai Zhongshan Hospital 56
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07128251
What this trial is testing

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Who this might be right for
Hepatocellular Carcinoma (HCC)ImmunotherapyPD-1+2 more
Anhui Provincial Hospital 47
Testing effectiveness (Phase 2)Looking for participantsNCT07110064
What this trial is testing

QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Who this might be right for
Advance Pancreatic Cancer
Du Juan 80
Next Page